[Fresh plasma and concentrates of clotting factors for therapy of perioperative coagulopathy: what is known?].
Acquired, perioperative coagulopathy often develops due to acute bleeding. In the case of primarily healthy patients with normal bone marrow and liver functions, a lack of coagulation factors initiates coagulopathy before secondary thrombopenia arises. Replacement of coagulation factors can be performed by infusion of fresh plasma (single donor or pooled plasma) or concentrates of clotting factors. Fresh plasma as well as concentrates of clotting factors available in German-speaking countries are of high quality and fulfil all safety standards. Undesirable side-effects due to transmission of infections and immunological reactions are--in all probability--more uncommon for virus-inactivated plasma and clotting factors than for single donor plasma. In contrast, thromboembolic complications are unlikely when using fresh frozen plasma, because it contains a balanced ratio of pro-coagulatory and anti-coagulatory factors. For virus-inactivated pooled plasma and concentrates of clotting factors, sporadic reports of thromboembolic events have been published. Concentrates of clotting factors can be stored easily and are rapidly prepared for use. In contrast, fresh frozen plasma has to be thawed before application leading to a significant delay in the schedule. During activated hemostasis, the half-life of clotting factors is significantly reduced in comparison to a stable physiological situation. In the case of perioperative coagulopathy higher dosages of fresh plasma and clotting factors than those recommended in published guidelines are often necessary for successful treatment. When using fresh plasma for coagulation therapy the resulting volume load must be considered. In conclusion, a modern concept of perioperative coagulation management should include fresh plasma as well as concentrates of clotting factors. The anesthetist should be familiar with the available components and be able to consider and adapt them to the individual situation.
Heindl
B
B
Klinik für Anaesthesiologie, Ludwig-Maximilians-Universität, Nussbaumstr. 20, 80336, München. Bernhard.Heindl@med.uni-muenchen.de
Spannagl
M
M
D001778:Blood Coagulation Disorders / Q000097:blood / Q000188:drug therapy*; D001779:Blood Coagulation Factors / Q000009:adverse effects / Q000627:therapeutic use*; D006489:Hemostatic Techniques; D006801:Humans; D007431:Intraoperative Complications / Q000097:blood / Q000188:drug therapy; D019990:Perioperative Care; D010949:Plasma; D011183:Postoperative Complications / Q000097:blood / Q000188:drug therapy
D001779:Blood Coagulation Factors